| # | Drug | Count |
|---|---|---|
| 0 | RITUXIMAB | 1513 |
| 1 | CYCLOPHOSPHAMIDE | 1305 |
| 2 | CYCLOPHOSPHAMIDE FOR INJECTION | 1305 |
| 3 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 1305 |
| 4 | DOXORUBICIN | 1181 |
| 5 | PREDNISONE | 1003 |
| 6 | DEXAMETHASONE | 541 |
| 7 | DEXAMETHASONE 1.5 MG | 541 |
| 8 | CYTARABINE | 502 |
| 9 | ETOPOSIDE | 483 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | POLATUZUMAB VEDOTIN | 391 | 0.0383 |
| 1 | GLOFITAMAB | 78 | 0.0288 |
| 2 | MOSUNETUZUMAB | 28 | 0.0253 |
| 3 | BENDAMUSTINE HCL | 302 | 0.0193 |
| 4 | CARMUSTINE | 77 | 0.0163 |
| 5 | LONCASTUXIMAB TESIRINE | 6 | 0.0146 |
| 6 | EPCORITAMAB-BYSP | 19 | 0.0142 |
| 7 | IFOSFAMIDE FOR INJECTION | 294 | 0.0137 |
| 8 | DOXORUBICIN | 1181 | 0.0131 |
| 9 | ETOPOSIDE PHOSPHATE | 21 | 0.0128 |
| # | Drug class | Count |
|---|---|---|
| 0 | CD20-directed Cytolytic Antibody [EPC] | 1551 |
| 1 | Corticosteroid [EPC] | 1437 |
| 2 | Alkylating Drug [EPC] | 1374 |
| 3 | Platinum-based Drug [EPC] | 736 |
| 4 | Nucleoside Metabolic Inhibitor [EPC] | 505 |
| 5 | Topoisomerase Inhibitor [EPC] | 483 |
| 6 | Folate Analog Metabolic Inhibitor [EPC] | 301 |
| 7 | Thalidomide Analog [EPC] | 167 |
| 8 | Kinase Inhibitor [EPC] | 122 |
| 9 | CD19-directed Chimeric Antigen Receptor [EPC] | 106 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 97 | 0.0240 |
| 1 | CD19-directed Chimeric Antigen Receptor [EPC] | 106 | 0.0104 |
| 2 | Amino Acid Hypertonic Solution [EPC] | 1 | 0.0063 |
| 3 | Topoisomerase Inhibitor [EPC] | 483 | 0.0063 |
| 4 | Alkylating Drug [EPC] | 1374 | 0.0056 |
| 5 | CD20-directed Cytolytic Antibody [EPC] | 1551 | 0.0049 |
| 6 | Platinum-based Drug [EPC] | 736 | 0.0027 |
| 7 | Nucleoside Metabolic Inhibitor [EPC] | 505 | 0.0018 |
| 8 | Hematopoietic Stem Cell Mobilizer [EPC] | 2 | 0.0013 |
| 9 | Corticosteroid [EPC] | 1437 | 0.0011 |